Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has earned an average rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.2857.

TSHA has been the topic of several research reports. JMP Securities raised their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Chardan Capital raised their price objective on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Wells Fargo & Company raised their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th.

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP boosted its holdings in shares of Taysha Gene Therapies by 17.7% in the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company's stock worth $29,089,000 after purchasing an additional 1,892,500 shares during the period. Jefferies Financial Group Inc. grew its position in shares of Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock worth $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth $11,178,000. Tybourne Capital Management HK Ltd. raised its position in shares of Taysha Gene Therapies by 10.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company's stock worth $9,459,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Taysha Gene Therapies by 3.5% in the 2nd quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company's stock worth $8,765,000 after acquiring an additional 128,840 shares in the last quarter. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Stock Up 2.1%

TSHA traded up $0.06 during trading on Tuesday, reaching $2.90. The stock had a trading volume of 2,030,602 shares, compared to its average volume of 2,652,497. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $3.31. The company has a market capitalization of $791.12 million, a price-to-earnings ratio of -8.53 and a beta of 0.98. The stock's 50 day moving average is $2.69 and its two-hundred day moving average is $2.23. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The company had revenue of $1.99 million during the quarter, compared to analysts' expectations of $1.61 million. As a group, analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.